GSK Bets on Long-Acting Biologics and AI to Reshape Respiratory Care

GSK is advancing its respiratory and immunology pipeline through longer-acting biologics, more targeted patient selection, and combination-treatment approaches. The update signals continued R&D focus in key therapeutic areas but provides no clinical data, financial targets, or regulatory milestones.